Catalyst

Slingshot members are tracking this event:

Japaense Ministry of Health Grants Priority Review to AbbVie's (ABBV) Marketing Application for Glecaprevir/Pibrentasvir (G/P) in Treatment of Hepatitis C Virus (HCV) Infection

Source Link:
http://www.prnewswire.com/news-releases/abbvie-granted-priority-review-in-japan-for-its-investigational-regimen-of-glecaprevirpibrentasvir-gp-for-the-treatment-of-all-major-genotypes-of-chronic-hepatitis-c-300423027.html

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
ABBV
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Mar 14, 2017
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Japanese Ministry Of Health, Priority Review, Marketing Application, Glecaprevir, Pibrentasvir, G/p, Hepatitis C Virus
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.